Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report

“… 3 , 4 , 5 , 6 Furthermore, there is a growing body of literature suggesting the potential therapeutic efficacy of targeted agent rechallenge (predominantly with the EGFR TKI osimertinib) after intervening therapy in patients with NSCLC. 7 , 8 …”

Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non–Small-Cell Lung Cancer: Regulatory Considerations

“…However, the available preliminary evidence suggests that rechallenge with osimertinib may induce tumor responses after intervening lines of therapy, suggesting that an arm of EGFR TKI alone may be justified. [12][13][14][15] In these circumstances, consideration may be given to a four-arm randomized factorial trial design, which includes an EGFR TKI-alone arm, a novel therapy-alone arm, a combination regimen arm, and a control arm.…”